AI-Native Scoping Reviews & Evidence Mapping

To comprehensively map the existing evidence on inhaled insulin, synthesizing findings on its glycemic efficacy, safety, pharmacokinetic/pharmacodynamic properties, patient acceptability, and role in special populations, in order to delineate its current clinical utility and identify critical knowledge gaps. The review uses 82 references and builds its evidence map from 168 original studies with 1087562 total participants/sample observations (topic-deduplicated ΣN). Overall, the evidence indicates that inhaled technosphere insulin offers a clinically viable, ultra-rapid prandial option that is…

RAS/KRAS inhibition has finally moved from “undruggable” promise to therapeutic reality, but this review shows why single-agent targeting is rarely enough. The full read maps 705 original studies to clarify how allele-specific, pan-RAS, RAS(ON), combination, resistance-monitoring, and immune/radiotherapy strategies may shape the next generation of durable cancer control.

Semaglutide is not just a weight-loss drug — this review maps how it reaches across obesity, diabetes, cardiovascular disease, kidney protection, liver disease, and emerging neurologic pathways, while separating strong evidence from hype. The full paper is worth reading because it shows where semaglutide truly delivers the biggest clinical gains, where the safety and durability limits begin, and which future uses may matter most.

Prolonged fasting is not a simple wellness shortcut: this evidence map shows it as a powerful metabolic stressor that can shift fuel use, inflammation, glucose control, gut biology, and endocrine signaling — but also expose serious risks in diabetes, pregnancy, surgery, frailty, and inherited metabolic disease. The full evidence map separates where fasting looks adaptive, therapeutic, diagnostic, or harmful, helping readers move beyond fasting hype toward phenotype-matched, supervised, and clinically realistic use.